XPlore Inc., a biotechnology company, supplies financial information for both years 2019 and 2020 (all the numbers, except for share data, are shown in thousands of dollars). Estimated cost of capital for all its financing is 10,5%. XPlore Inc. Income statements (\$ in thousands) XPlore Inc. Balance Sheets ( $ in thousands) ASSETS 2019 2020 \begin{tabular}{lcc} Cash & $270 & $446 \\ \hline Accounts receivable & 630 & 824 \\ Inventories & 540 & 702 \\ \hline Other current assets & 113 & 144 \\ \hline Total current assets & $1,553 & $2,115 \\ \hline Gross fixed assets & $4,185 & $4,455 \\ \hline Accumulated depreciation & $1,530) & $1,980) \\ \hline Net fixed assets & $2,655 & $4,475 \\ \hline Total assets & $4,208 & \end{tabular} LIABILITIES (DEBT) AND EQUITY AccountspayableShort-termnotespayableTotalcurrentliabilitiesLong-termdebtTotalliabilities$360225$5851,125$1,710$576270$8461.193$2,039 Common equity: Common stock (par \& paid in capital) $990$990 Retained eamings Total common equity 1,508$2,498$4,2081,562$2,552$4,590 Total liabilities and equity Based on the topics learnt in class prepare a financial analysis of XPlore Inc. and its financial performance, comparing the firm's performance between 2 years. For your analysis and evaluation, please consider the following: a) computation common sized income statements for both years (10 points) b) computation common sized balance sheets for both years (10 points) c) computation of applicable financial ratios (20 points) (Current ratio, Acid-test ratio, Days in receivables, Days in inventory, Operating return on assets, Operating profit margin, Total asset turnover Fixed asset turnover, Debt ratio, Times interest earned, Return on equity) d) computation price/earnings ratios and market/book ratios ( 10 points) e) Interpret your results briefly, what would you recommend to XPlore's management? (10 points) All percentages should be rounded to the second decimal place